AESOP TECHNOLOGY
  • DxPrime
  • DxCode
  • Medigator for Oncology
  • RxPrime
  • Research
  • AESOP Talks
  • News
  • About
  • EN/CH

MedGuard is now called

Request More ​Information

Medication Error is Common and Life-threatening

​Prescription
​errors
​happen
every
two second

2 in 5
patients
are harmed
while receiving
​healthcare

A right start is half the battle won​

Medication errors can occur at any stage of the medication-use process, leading to severe consequences for patients. However, these errors are preventable. More than half of medication errors occur during the prescribing phase. RxPrime helps identify and prevent errors at this critical stage, including look-alike-sound-alike errors, where medications with similar names or sounds cause confusion. By using RxPrime early in the prescribing process, doctors can ensure the correct medication is prescribed, improving patient safety.

Picture
|   The Medication-Use Process   |

Better Decision Support for Unexplained Medication

RxPrime helps to detect potential errors in prescriptions. It provides alternative recommendations based on the patient's diagnoses, age, and gender, considering multiple perspectives, including the department and hospital-wise. It offers real-time decision support without disrupting the clinical consultation process. In this way, RxPrime enhances prescriptions' accuracy and safety, reducing the risk of medication errors and improving patient outcomes.

U.S., Taiwan Partner to Improve Patient Safety​

According to our clinical study conducted in partnership with Harvard Medical School and Taipei Medical University, RxPrime’s accuracy ranged from 79% to 85%. The study employed an international federated learning approach, a method of training machine learning models on decentralized data to ensure the transferability of results. The findings demonstrated that RxPrime effectively identifies potential prescription errors and provides accurate recommendations when applied across different countries.

​3.2B Prescription Database

RxPrime is built on a vast database of well-coded prescriptions, comprising over 3.2 billion records and 2.4 billion association rules. This data supports medication decision-making by analyzing both explicit and tacit knowledge, as well as prescribing behaviors from doctors.​

Dual AI ​Engine

Powered by a dual AI engine with customized algorithms for medication safety, RxPrime continuously self-improves and reduces alert fatigue. It analyzes large data sets to identify patterns and trends not immediately apparent to humans, thereby providing more accurate and relevant support during prescribing.
Picture
In the light of increasing complexity of healthcare and the aging population, there is a very clear trend that there are more medical errors happening every day. Tools that our offer by companies like AESOP provide us a way to tackle this serious worldwide problem with innovative AI tools. We are very hopeful that in the future AI is going to help us reduce error and improve patient safety significantly.

Dr. Yu-Chuan Jack Li
Distinguished Professor
College of Medical Science and Technology
​Taipei Medical University
Chief & Dermatologist
Taipei Municipal Wanfang Hospital
President
​International Medical Informatics Association
Picture
We’re living in an exciting time. We now have more data because of the EHRs that we’ve installed across the country in the world. Yet we’ve not built tools that allow us to harvest that data. AI and machine learning provide new opportunities to improve medication safety. Approaches like AESOP will allow us to understand multiple drug interactions as well as age and drug interactions, and diagnosis and age interactions, so that we can improve medication safety for all of our citizens. ​

Prof. Charles Safran
Chief
​Harvard Medical School
Division of Clinical Informatics
Beth Israel Deaconess Medical Cente
r

Request More
​Information

Submit
AESOP TECHNOLOGY
[email protected]
​Privacy Policy
© AESOP Technology 2025
  • DxPrime
  • DxCode
  • Medigator for Oncology
  • RxPrime
  • Research
  • AESOP Talks
  • News
  • About
  • EN/CH